For the quarter ending 2026-03-31, ZVSA had $200,882 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Non-cash rent expense | - | 0 | - | 0 |
| Operating lease liability | - | 0 | - | 0 |
| Depreciation of fixed assets | - | 0 | - | 0 |
| Net loss | -1,793,381 | -678,572 | -19,805,559 | -4,468,247 |
| Impairment of in-process research and development | - | 0 | 18,647,903 | - |
| Stock-based compensation | 55,872 | 17,353 | 73,988 | 131,490 |
| Issuance of common stock pursuant to vendor agreements | - | 0 | 29,600 | 210,400 |
| Fair value option loss on convertible notes | -344,000 | - | - | - |
| Write-off of deferred offering costs | - | 57,238 | - | - |
| Change in fair value of equity payable | 28,171 | - | - | - |
| Deferred tax (benefit) provision | - | 0 | -851,659 | 0 |
| Change in fair value of warrant liabilities | -16,000 | - | - | - |
| Prepaid expenses and other current assets | 92,374 | -66,553 | -80,557 | 193,876 |
| Vendor deposits | 14,484 | 154,879 | -1,652 | 8,700 |
| Accounts payable | 111,885 | 318,262 | 314,798 | 56,208 |
| Accrued expenses and other current liabilities | 548,225 | -349,402 | 105,112 | 961,545 |
| Net cash used in operating activities | -799,118 | -413,689 | -1,406,912 | -3,293,780 |
| Exercise of warrants | - | 0 | - | 0 |
| Payment of offering costs | - | -12,511 | 12,511 | - |
| At the market issuance of stock proceeds | - | 0 | - | - |
| Private placement of warrants | - | 0 | 0 | 1,999,791 |
| Warrant inducement offer - exercise proceeds | - | 0 | 2,051,852 | - |
| Deferred offering costs | - | - | - | 17,928 |
| Exercise of pre-funded warrants | - | 0 | 0 | 210 |
| Registration and issuance costs associated with warrant issuance | - | 0 | 219,487 | 147,131 |
| Proceeds from issuance of convertible notes and warrants | 1,000,000 | - | - | - |
| Net cash provided by financing activities | 1,000,000 | -12,511 | 1,862,804 | 1,834,942 |
| Net increase in cash | 200,882 | -426,200 | 455,892 | -1,458,838 |
| Cash - beginning of period | 101,778 | 527,978 | 1,530,924 | - |
| Cash - end of period | 302,660 | 101,778 | 527,978 | - |
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)